Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma |
| |
Authors: | Bo Jia Yuankai Shi Suyi Kang Sheng Yang Shaoxuan Hu Yexiong Li Mei Dong Weihu Wang Jianliang Yang Liqiang Zhou Peng Liu Shengyu Zhou Yan Qin Lin Gui Changgong Zhang Hua Lin Shanshan Chen Lin Wang Xiaohui He |
| |
Affiliation: | 1.Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China; 2.Department of Radiation Oncology, 3.Department of Medical Record Library, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China |
| |
Abstract: | BackgroundThe role of rituximab in combination with CHOP regimen in patients with stage I diffuse large B-cell lymphoma (DLBCL) remains to be defined. We aimed to compare CHOP plus rituximab (R-CHOP) with CHOP alone and determine the value of radiotherapy in these patients.MethodsBetween 2003 and 2009, 140 untreated patients with stage I DLBCL were retrospectively analyzed in this study.ResultsSeventy-eight patients were treated in R-CHOP group and 62 in CHOP group. Ninety-one patients received additional radiotherapy at the end of chemotherapy. The different treatment groups were well-balanced with respect to baseline characteristics. Complete response (CR) rate was 77% both in R-CHOP and CHOP groups (P=0.945). After a median follow-up period of 56 months, patients received R-CHOP regimen had similar 5-year progression-free survival (PFS) (76% vs. 85%; log-rank P=0.215) and 5-year overall survival (OS) (90% vs. 96%; log-rank P=0.175) compared with those with CHOP alone. Patients with radiotherapy had significantly increased 5-year PFS compared with those who had chemotherapy alone (86% vs. 71%; log-rank P=0.005). At multivariate analysis, patients who had CR (P=0.008) and received radiotherapy (P=0.003) were significantly associated with superior PFS.ConclusionsCHOP alone could be as effective as R-CHOP regimen and additional radiotherapy would be necessary for stage I or stage I non-bulky DLBCL patients. |
| |
Keywords: | Diffuse large B-cell lymphoma (DLBCL) stage I R-CHOP radiotherapy prognosis |
|
|